Skip to main content
Top
Published in: Acta Diabetologica 4/2013

01-08-2013 | Original Article

Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults

Authors: Altan Onat, Günay Can, Gökhan Çiçek, Erkan Ayhan, Yüksel Doğan, Hasan Kaya

Published in: Acta Diabetologica | Issue 4/2013

Login to get access

Abstract

We determined in non-diabetic persons the risk of fasting and non-fasting glucose levels for pre-diabetes, diabetes, and coronary heart disease (CHD), including the roles of serum C-reactive protein (CRP) and HDL cholesterol, and delineated risk profiles of the pre-diabetic states. Over 7¼ years, 2,619 middle-aged Turkish adults free of diabetes and CHD were studied prospectively. Using different serum glucose categories including impaired fasting glucose (IFG, 6.1–6.97 mmol/L) and impaired glucose tolerance (IGT), outcomes were analyzed by Cox regression. IFG was identified at baseline in 112 and IGT in 33 participants. Metabolic syndrome components distinguished individuals with IFG from those with normoglycemia. Participants with IGT tended to differ from adults in normal postprandial glucose categories in regard to high levels of triglycerides, apoA-I, and CRP. Diabetes risk, adjusted for sex, age, waist circumference, CRP, and HDL cholesterol, commenced at a fasting 5.6–6.1 mmol/L threshold, was fourfold at levels 6.1–6.97 mmol/L. Optimal glucose values regarding CHD risk were 5.0–6.1 mmol/L. Fasting and postprandial glucose values were not related to CHD risk in men; IGT alone predicted risk in women (HR 3.74 [1.16;12.0]), independent of age, systolic blood pressure, non-HDL cholesterol, waist circumference, smoking status, and CRP. HDL cholesterol was unrelated to the development of IFG, IGT, and diabetes, while CRP elevation independently predicted the development of diabetes. IGT independently predicts CHD risk, especially in women. HDL dysfunction associated with low-grade inflammation is a co-determinant of pre-diabetic states and their progression to diabetes.
Literature
1.
go back to reference Festa A, D’Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549–1555PubMedCrossRef Festa A, D’Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549–1555PubMedCrossRef
2.
go back to reference Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B (2007) American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759PubMedCrossRef Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B (2007) American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759PubMedCrossRef
3.
go back to reference Zhang L, Qiao Q, Tuomilehto J, Hammar N, Alberti KG, Eliasson M, Heine RJ, Stehouwer CD, Ruotolo G, DECODE Study Group (2008) Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: the DECODE study. Diabetes Res Clin Pract 82:364–377PubMedCrossRef Zhang L, Qiao Q, Tuomilehto J, Hammar N, Alberti KG, Eliasson M, Heine RJ, Stehouwer CD, Ruotolo G, DECODE Study Group (2008) Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: the DECODE study. Diabetes Res Clin Pract 82:364–377PubMedCrossRef
4.
go back to reference Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, Ballantyne CM (2007) Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30:325–331PubMedCrossRef Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, Ballantyne CM (2007) Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30:325–331PubMedCrossRef
5.
go back to reference Haffner SM, Miettinen H, Stern MP (1997) Relatively more atherogenic coronary heart disease risk factors in prediabetic women than prediabetic men. Diabetologia 40:711–717PubMedCrossRef Haffner SM, Miettinen H, Stern MP (1997) Relatively more atherogenic coronary heart disease risk factors in prediabetic women than prediabetic men. Diabetologia 40:711–717PubMedCrossRef
6.
go back to reference Zhang L, Qiao Q, Tuomilehto J, Hammar N, Ruotolo G, Stehouwer CD, Heine RJ, Eliasson M, Zethelius B, DECODE Study Group. (2009) The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 206:298–302PubMedCrossRef Zhang L, Qiao Q, Tuomilehto J, Hammar N, Ruotolo G, Stehouwer CD, Heine RJ, Eliasson M, Zethelius B, DECODE Study Group. (2009) The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 206:298–302PubMedCrossRef
7.
go back to reference Moebus S, Stang A, Möhlenkamp S, Dragano N, Schmermund A, Slomiany U, Hoffmann B, Bauer M, Broecker-Preuss M, Mann K, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Group (2009) Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort—results of the Heinz Nixdorf Recall study. Diabetologia 52:81–89PubMedCrossRef Moebus S, Stang A, Möhlenkamp S, Dragano N, Schmermund A, Slomiany U, Hoffmann B, Bauer M, Broecker-Preuss M, Mann K, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Group (2009) Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort—results of the Heinz Nixdorf Recall study. Diabetologia 52:81–89PubMedCrossRef
8.
go back to reference Björnholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E (1999) Fasting blood glucose: an underestimated risk factor for cardiovascular death. Diabetes Care 22:45–49PubMedCrossRef Björnholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E (1999) Fasting blood glucose: an underestimated risk factor for cardiovascular death. Diabetes Care 22:45–49PubMedCrossRef
9.
go back to reference Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert K, Köhler C (1999) Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16:212–218PubMedCrossRef Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert K, Köhler C (1999) Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16:212–218PubMedCrossRef
10.
go back to reference Abdul-Ghani MA, Williams K, DeFronzo R, Stern M (2006) Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29:1613–1618PubMedCrossRef Abdul-Ghani MA, Williams K, DeFronzo R, Stern M (2006) Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29:1613–1618PubMedCrossRef
11.
go back to reference Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112PubMedCrossRef Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112PubMedCrossRef
12.
go back to reference Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMedCrossRef Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMedCrossRef
13.
go back to reference Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M (2007) Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care 30:354–359PubMedCrossRef Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M (2007) Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care 30:354–359PubMedCrossRef
14.
go back to reference Succurro E, Marini MA, Grembiale A, Lugarà M, Andreozzi F, Sciacqua A, Hribal ML, Lauro R, Perticone F, Sesti G (2009) Differences in cardiovascular risk profile based on relationship between post-load plasma glucose and fasting plasma levels. Diabetes Metab Res Rev 25:351–356PubMedCrossRef Succurro E, Marini MA, Grembiale A, Lugarà M, Andreozzi F, Sciacqua A, Hribal ML, Lauro R, Perticone F, Sesti G (2009) Differences in cardiovascular risk profile based on relationship between post-load plasma glucose and fasting plasma levels. Diabetes Metab Res Rev 25:351–356PubMedCrossRef
15.
go back to reference Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef
16.
go back to reference Onat A, Can G, Ayhan E, Kaya Z, Hergenç G (2009) Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58:1393–1399PubMedCrossRef Onat A, Can G, Ayhan E, Kaya Z, Hergenç G (2009) Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58:1393–1399PubMedCrossRef
17.
go back to reference Onat A, Hergenç G, Bulur S, Uğur M, Küçükdurmaz Z, Can G (2010) The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142:72–79PubMedCrossRef Onat A, Hergenç G, Bulur S, Uğur M, Küçükdurmaz Z, Can G (2010) The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142:72–79PubMedCrossRef
18.
go back to reference Onat A, Hergenç G (2011) Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:499–512PubMedCrossRef Onat A, Hergenç G (2011) Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:499–512PubMedCrossRef
19.
20.
go back to reference Genuth S, Alberti KG, Bennett P et al (2003) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus: the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26:3160–3167PubMedCrossRef Genuth S, Alberti KG, Bennett P et al (2003) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus: the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26:3160–3167PubMedCrossRef
21.
go back to reference World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva (WHO/NCD/NCS/99.2) World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva (WHO/NCD/NCS/99.2)
22.
go back to reference Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G (2007) Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191:182–190PubMedCrossRef Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G (2007) Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191:182–190PubMedCrossRef
23.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
24.
go back to reference Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. World Health Organization, Geneva, pp 124–127 Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. World Health Organization, Geneva, pp 124–127
25.
go back to reference Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR (2007) Australian Diabetes Society; Australian Diabetes Educators Association. Med J Aust 186:461–465PubMed Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR (2007) Australian Diabetes Society; Australian Diabetes Educators Association. Med J Aust 186:461–465PubMed
26.
go back to reference Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914PubMedCrossRef Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914PubMedCrossRef
27.
go back to reference Festa A, Hanley AJ, Tracy RP, D’Agostino R Jr, Haffner SM (2003) Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822–1830PubMedCrossRef Festa A, Hanley AJ, Tracy RP, D’Agostino R Jr, Haffner SM (2003) Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822–1830PubMedCrossRef
28.
go back to reference Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef
29.
go back to reference Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87–92PubMedCrossRef Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87–92PubMedCrossRef
30.
go back to reference Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342–374PubMedCrossRef Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342–374PubMedCrossRef
31.
go back to reference Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723PubMedCrossRef Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723PubMedCrossRef
32.
go back to reference Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef
33.
go back to reference Qiao Q, Pyörala K, Pyörala M, Nissinen A, Lindström J, Tilvis R, Tuomilehto J (2002) Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 23:1267–1275PubMedCrossRef Qiao Q, Pyörala K, Pyörala M, Nissinen A, Lindström J, Tilvis R, Tuomilehto J (2002) Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 23:1267–1275PubMedCrossRef
34.
go back to reference Waterworth D, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P (1999) ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 99:1872–1877PubMedCrossRef Waterworth D, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P (1999) ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 99:1872–1877PubMedCrossRef
Metadata
Title
Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults
Authors
Altan Onat
Günay Can
Gökhan Çiçek
Erkan Ayhan
Yüksel Doğan
Hasan Kaya
Publication date
01-08-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0313-x

Other articles of this Issue 4/2013

Acta Diabetologica 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.